Inherited mutations in the gene BRCA2 significantly increase the risk of carriers to breast and ovarian cancers.  BRCA2, a crucial player in the body& | Cancer ...

A new study led by scientists at NYU Langone Health sheds light on how the major cancer gene BRCA2 determines which cancer cells can be killed by a class of precision cancer drugs called PARP ...

Mutations in BRCA2—a gene known to repair damaged DNA and suppress tumor formation—can predict an individual's predisposition to develop breast cancer, ovarian, prostate, pancreatic, and other ...

The primary job of BRCA2 is to regulate RAD51, a key player in the accurate recombination of DNA during cell division. The researchers found, to their surprise, that when PARP inhibitors ...

This blocks RAD51 access and halts proper repair, causing fatal damage to cancer cells—a mechanism that explains the greater vulnerability of BRCA2-deficient tumor cells to PARP inhibitors.